# Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

> **NCT05034133** · PHASE2 · UNKNOWN · sponsor: **Beijing Haidian Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05034133
- **Lead sponsor:** Beijing Haidian Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05034133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05034133, "Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05034133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*